Onconetix Inc (ONCO)
1.64
-0.08
(-4.65%)
USD |
NASDAQ |
Nov 14, 16:00
1.74
+0.10
(+6.10%)
After-Hours: 20:00
Onconetix Revenue (Quarterly): 0.7048M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 0.7048M |
March 31, 2024 | 0.7004M |
Date | Value |
---|---|
December 31, 2023 | 0.0585M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.0585M
Minimum
Dec 2023
0.7048M
Maximum
Jun 2024
0.4879M
Average
0.7004M
Median
Mar 2024
Revenue (Quarterly) Benchmarks
CEL-SCI Corp | -- |
AIM ImmunoTech Inc | 0.05M |
IGC Pharma Inc | 0.272M |
NovaBay Pharmaceuticals Inc | 2.441M |
Protalix BioTherapeutics Inc | 13.47M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -14.31M |
Total Expenses (Quarterly) | 2.822M |
EPS Diluted (Quarterly) | -25.60 |
Enterprise Value | 22.53M |
Gross Profit Margin (Quarterly) | 14.29% |
Profit Margin (Quarterly) | -2.03K% |
Earnings Yield | -6.63K% |